GLP-1 drugs have become wildly popular as weight-loss medications, but with their increased use has come concern over the long-term safety of this class of drugs
We also considered the strength of the evidence (the magnitude of observed effects) and the consistency of findings across various studies or sources
The trial's UK chief investigator, Professor John Wilding from the University of Liverpool, said: 'This is a significant advance in the treatment of obesity
Conversely, there was a possible reduction in activation within the secondary somatosensory cortex, an area involved in processing sensory information, specifically when under the influence of visual stimuli, differing from responses observed with the placebo
Key Factors: Fatty acid side chains (lipophilic modification) Non-natural amino acid substitutions Impact: These modifications: Alter peptide fragmentation behavior Reduce predictability in MS/MS spectra Complicate sequence confirmation and data interpretation 2
